Pharmacokinetics of saquinavir after intravenous and oral dosing of Saquinavir: Hydroxybutenyl-β-cyclodextrin formulations

Biomacromolecules

Volumn 9, Issue 1, 2008, Pages 305-313

  Buchanan, Charles M ^a   Buchanan, Norma L ^a   Edgar, Kevin J ^a,b   Little, James L ^a   Ramsey, Michael G ^a   Ruble, Karen M ^a   Wacher, Vincent J ^a,c   Wempe, Michael F ^a,d  

^a EASTMAN CHEMICAL COMPANY   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c East Tennessee State University ^*  (United States)

^d EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL BIOAVAILABILITY; ORAL DELIVERY; ORAL DOSING; SAQUINAVIR;

CYCLODEXTRINS; DISSOLUTION; PHARMACOKINETICS; SALTS; SOLUBILITY;

ENZYME KINETICS;

BASE; BETA CYCLODEXTRIN DERIVATIVE; HYDROXYBUTENYL BETA CYCLODEXTRIN; MACROGOL; MICROCRYSTALLINE CELLULOSE; SAQUINAVIR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; PRIORITY JOURNAL; RAT; STRUCTURE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; WISTAR HANNOVER RAT;

ADMINISTRATION, ORAL; ANIMALS; BETA-CYCLODEXTRINS; HIV PROTEASE INHIBITORS; INJECTIONS, INTRAVENOUS; RATS; RATS, WISTAR; SAQUINAVIR;

RATTUS;

EID: 38849159071     PISSN: 15257797     EISSN: None     Source Type: Journal    
DOI: 10.1021/bm700827h     Document Type: Article

References (28)

1. UNAIDS/WHO AIDS Epidemic Update; www.unaids.org/en/HIV⊣ta/epi2006/ default.asp, December 2006.
2. Huisman, M. T.; Smit, J. W.; Wiltshire, H. R.; Hoetelmans, R. M. W.; Beijnen, J. H.; Schinkel, A. H. Mol. Pharm. 2001, 59, 806-813.
3. Gao, W.; Kishida, T.; Kageyama, M.; Kimura, K.; Yoshikawa. Y.; Shibata, N.; Takada, K. Antiviral Chem. Chemother. 2002, 13, 17-26.
4. Tam-Zaman, N.; Tam, Y. K.; Tawfik, S.; Wiltshire, H. Pharm. Res. 2004, 21, 436-442.
5. Sinko, P. J.; Kunta, J. R.; Usansky, H. H.; Perry, B. A. J. Pharmacol. Exp. Ther. 2004, 310, 359-366.
6. Invirase; Food and Drug Administration, www.fda.gov/medwatch/SAFETY/2003/ 03DEC_PI/Invirase_PI.pdf. Fortovase; Food and Drug Administration, www.fda.gov/cder/foi/label/2002/20828s101b1.pdf.
7. Thompson, D. O. Crit. Rev. Ther. Drug Carrier Syst. 1997, 14, 1-104.
8. Szejtli, J. Supramol. Chem. 1995, 6, 217-223.
9. Uekama, K.; Hirayama, F.; Irie, T. Chem. Rev. 1998, 98, 2045-2076.
10. Szejtli, J. Pharm. Technol. 1991, 15, 24-38.
11. Boudad, H.; Legrand, P.; Lebas, G.; Cheron, M.; Duchene, D.; Ponchel, G. Int. J. Pharm. 2001, 218, 113-124.
12. Boudad, H.; Legrand, P.; Appel, M.; Coconnier, M.-H.; Ponchel, G. S.T.P. Pharma Sci. 2001, 11, 369-375.
13. Johnson, M. D.; Hoesterey, B. L.; Anderson, B. D. J. Pharm. Sci. 1994, 83, 1142-1146.
14. Buchanan, C. M.; Alderson, S. R.; Cleven, C. D.; Dixon, D. W.; Ivanyi, R.; Lambert, J. L.; Lowman, D. W.; Offerman, R. J.; Szejtli, J.; Szente, L. Carbohydr. Res. 2002, 327, 493-507.
15. Chen, T. M.; Shen, H.; Zhu, C. Comb. Chem. High Throughput Screening 2002, 5, 575-81.
16. Pan, L.; Ho, Q.; Tsutsui, K.; Takahashi, L. J. Pharm. Sci. 2001, 90, 521-529.
17. USP 28-NF 23 711; The United States Pharmacopoeial Convention, Inc., Webcom Limited, Canada 2412-24142005.
18. Little, J.; Wempe, M.; Buchanan, C. J. Chromatogr. B 2006, 833, 219-230.
19. Yang, L.; Wu, N.; Clement, R. P.; Rudewicz, P. J. J. Chromatogr. B 2004, 799, 271-280.
20. Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation; http://www.fda.gov/cder/guidance/4252fnl.pdf; U.S. Department of Health and Human Service, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine, 2001.
21. Rowland, M.; Tozer, T. N. Clinical Pharmacokinetics; Lippincott, Williams, & Wilkins: Philadelphia, PA, 1995.
22. Buchanan, C. M.; Buchanan, N. L.; Edgar, K. J.; Little, J. L.; Malcolm, M.; Ruble, K. M.; Wacher, V. J.; Wempe, M. F. J. Pharm. Sci. 2007, 96, 644-660.
23. Buchanan, C. M.; Buchanan, N. L.; Edgar, K. J.; Klein, S.; Little, J. L.; Ruble, K. M.; Wacher, V. J.; Wempe, M. F. J. Pharm. Sci. 2007, in press, doi:10.1002/jps.20878.
24. Wempe, M. F.; Rice, P. J.; Buchanan, C. M.; Buchanan, N. L.; Edgar, K. J.; Hanley, G. A.; Ramsey, M. G.; Skotty, J. S. J. Pharmacy and Pharmacology 2007, in press, doi.10.1211/jpp.59.6.0006.
25. Wempe, M. F.; Wacher, V. J.; Ruble, K. M.; Ramsey, M. G.; Edgar, K. J.; Buchanan, N. L.; Buchanan, C. M. Int. J. Pharm. 2007, in press, doi:10.1016/j.ijpharm.2007.06.002.
26. Alsenz, J.; Haenel, E. Pharm. Res. 2003, 20, 1961-1969.
27. Storch, C. H.; Theile, D.; Lindenmaier, H.; Haefeli, E.; Weiss, J Biochem. Pharmacol. 2007, 73, 1573-1581.
28. Ritschel, W. A.; Kearns, G. L. Handbook of Basic Pharmacokinetics Including Clinical Applications, 6th ed.American Pharmacists Association: Washington, DC 2004; Chapter 23.